NCT05132582 2026-03-16
HER2CLIMB-05
Seagen Inc.
Phase 3 Active not recruiting
Clinical Trials
16 trialsNCT03006172 2026-03-11
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Genentech, Inc.
Phase 1 Active not recruiting
NCT05593094 2026-02-25
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT05113251 2026-02-23
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT02320435 2026-02-12
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04158258 2026-02-12
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
Hoffmann-La Roche
Active not recruiting
NCT06771622 2026-02-04
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
FBD Biologics Limited
Phase 1/2 Active not recruiting
NCT07386938 2026-02-04
A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer
R-Pharm
Phase 3 Active not recruiting
NCT04208178 2026-02-02
EPIK-B2
Novartis
Phase 3 Active not recruiting
NCT02057133 2026-01-26
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Eli Lilly and Company
Phase 1 Active not recruiting
NCT05296798 2026-01-16
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT00781612 2025-12-24
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Genentech, Inc.
Phase 2 Active not recruiting
NCT04538742 2025-12-08
DB-07
AstraZeneca
Phase 1/2 Active not recruiting
NCT04514419 2025-11-21
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
BioRay Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT05802225 2025-07-20
PREFER
Biocad
Phase 3 Active not recruiting
NCT04188548 2025-06-04
EMBER
Eli Lilly and Company
Phase 1 Active not recruiting